Press Release Details

CERUS to Present at Morgan Stanley's 11th Annual European MedTech Trip

February, 19 2008

CONCORD, Calif.--(BUSINESS WIRE)--Feb. 19, 2008--Cerus Corporation (NASDAQ:CERS) announced today that company management will present at the Morgan Stanley 11th Annual European MedTech Trip at 8:00 a.m. at the Hotel Metropole in Brussels, Belgium on Tuesday, February 26. The meeting seeks to introduce U.S. institutional investors to medical technology companies with significant European operations.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

CONTACT: Cerus Corporation
William J. Dawson, 925-288-6053
Vice President, Finance & CFO
or
Vida Communication (On behalf of CERUS)
Stephanie Diaz, 415-675-7401

SOURCE: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600